Mankind Pharma Q1 FY27: Margin expansion and export momentum as domestic recovery firms up

Mankind Pharma opened FY27 with a quarter that combined steady growth with a visible improvement in profitability. In Q1 FY27, revenue from operations rose to INR 4,031 crore, up 12.9% year on year. EBITDA increased to INR 1,060 crore, translating into a 26.3% margin, up 250 basis points from Q1 FY26. Profit after tax grew 29.1% to INR 574 crore, taking PAT margin to 14.2%.

The performance was broad based. Domestic formulations excluding Consumer Healthcare grew 11.0% to INR 3,180 crore, supported by stronger chronic momentum and a recovery trend in acute therapies. Exports were the standout, rising 29.0% to INR 605 crore. Consumer Healthcare grew a modest 3.9% to INR 246 crore, partly impacted by the discontinuation of a cash and carry channel and a softer category environment.

The quarter, in numbers

The company’s Q1 FY27 results show a clean operating leverage story, driven mainly by a sharp improvement in gross margin and aided by lower finance costs. Gross margin rose 230 basis points year on year to 72.8%, which management attributed to pricing actions, a better mix as chronic contribution increased, and a favourable base effect from inventory related accruals in the prior year.

The CFO also noted that reported EBITDA margin expansion was primarily the outcome of gross margin improvement, with a smaller contribution from operating leverage. PAT growth benefited from lower finance cost following repayment of an INR 1,250 crore NCD tranche, though this was partly offset by a higher effective tax rate of 25.4% due to the shift to the new tax regime after the expiry of tax benefits for the Sikkim plant.

Domestic formulations: chronic mix shift continues, acute recovery visible

Management framed the domestic business narrative around structural levers rather than a one quarter burst. Domestic formulations excluding Consumer Healthcare grew 11% year on year. The company highlighted that secondary sales grew 12.7% versus IPM growth of 13.0% in Q1 FY27, with volume growth of 4.7% and continued strength in chronic.

A key metric management emphasized was the chronic share improvement. Chronic share excluding BSV increased by 80 basis points year on year to around 40% in Q1 FY27, supported by 19.4% growth in cardiac and 12.7% growth in anti-diabetes. The company reiterated its medium term intent to increase chronic share to 50%, with one management response pointing to a 4 to 5 year horizon.

Within acute therapies, the company noted sequential recovery across gastro, vitamins and gynaecology, which contributed to the improvement in acute performance. Management described the recovery as tied to rebuilding field execution following realignments, with attrition and vacancies said to have returned to normal levels.

Consumer Healthcare: a reset on channels, but brand shares improve

Consumer Healthcare grew 4% year on year in Q1 FY27, a softer trajectory versus the company’s larger domestic and export businesses. Management explained that growth was partly impacted by the base effect of discontinuing a cash and carry business, which was creating conflict with general trade.

Despite the subdued topline, management highlighted market share gains in key brands such as Manforce, Prega News and Gas-O-Fast. The channel mix also shifted in a direction the company appears to favour. Modern trade and e-commerce share increased to 15% from 11% a year ago, supported by 38% growth in that channel. Management indicated expectations of higher growth from Q2 onwards, describing a high single digit to double digit outlook for the remaining quarters.

Exports and BSV: growth accelerates, but execution stays independent

Exports revenue grew 29% in Q1 FY27. Management attributed this to strong BSV international performance along with good performance in the US, and noted that the company excluding BSV has launched one new product in Q1 FY27, taking total launched products in the US to 49.

On BSV, management corrected an analyst’s assertion and said FY26 growth was in the early teens and Q1 FY27 growth was around 21%. In the quarter, management indicated BSV domestic growth was around 17% and international growth around 25%, and reiterated guidance for high teens growth.

Importantly, the company reiterated that BSV is run independently operationally, with selective support where required. Management mentioned steps such as enhancement of biotech R and D capabilities and demand creation initiatives including greater gynaec coverage and IVF programs.

Margins, cash flow and leverage: progress with near-term watch-outs

The quarter’s profitability improvement was material, but management also highlighted the near-term uncertainties that could affect gross margin. The CFO noted potential compression over the next quarter or so due to rising commodity costs and a stronger dollar, while maintaining gross margin guidance of 71% plus and EBITDA margin guidance of 25.5% to 26.5% for FY27. A separate management response explicitly cited the West Asia crisis as the key reason for conservatism.

Working capital and cash conversion were softer in Q1. Net operating working capital days rose to 52 on a trailing 12 month basis, mainly due to higher inventory. Management indicated inventory levels were slightly above normal and expected rationalization in the coming quarters. Cash flow to EBITDA fell to 77% from 99% in Q1 FY26, which management attributed to the higher effective tax rate, working capital movement, and a base effect.

On leverage, the direction remained favourable. Net debt reduced to INR 3,377 crore as of 30 June 2026, with net debt to adjusted EBITDA at 0.9x. Management reiterated that it remains on track to repay acquisition related debt by FY28.

Takeaways

Mankind Pharma’s Q1 FY27 results reflect a company pushing for a higher quality growth mix while keeping a tight grip on profitability. Domestic formulations showed a recovery pattern, chronic share continued to inch up, and exports delivered strong growth. The main questions for the rest of FY27 sit around how margins behave as input costs rise, how quickly working capital normalizes, and whether Consumer Healthcare returns to a higher growth path after the channel reset.

Management’s stance was consistent: prioritize structural levers such as chronic expansion, specialty scaling and better field execution, while maintaining profitability guidance and reducing acquisition related leverage. If the company can sustain the domestic recovery and keep export momentum intact, the quarter’s improvement in operating metrics provides a base for the double digit growth aspiration management reiterated for the year.